Solara Active Pharma Sciences Limited was incorporated on February 23, 2017, emerging as a specialized Active Pharmaceutical Ingredients (API) manufacturer with a global footprint. The company was formed through the demerger of the API business from Strides Shasun Ltd (currently Stride Pharma Sciences) and subsequently acquired the human API business from Sequent Scientific Ltd during the same period, establishing itself as a pure-play API company.
Solara Active Pharma Sciences Ltd is engaged in the manufacturing, production, processing, formulating, sale, import, export, merchandising, distribution, and trading of APIs. It offers a range of high-value commercial APIs and contract manufacturing services across 73+ countries. With operations spanning 75 countries, the company primarily deals in APIs and develops over 80 commercial APIs predominantly in anthelmintic, antimalarial, anti-infective, neuromuscular, insomnia, antipsychotic, and hyperkalemia segments.
Solara Active Pharma Sciences Ltd currently holds a market capitalization of ₹2,293 crore as of recent trading sessions, marking its position as a significant player in the pharmaceutical API sector. The company's 52-week high share price is ₹885.95 and its 52-week low share price is ₹441.10.
The company's financial performance reflects the dynamic nature of the API market:
* Q1 FY25 Results: Solara Active Pharma Sciences reported a consolidated net loss of ₹2.10 crore in the March 2025 quarter. Net sales for March 2025 totaled ₹273.01 crore, marking an 8.82% year-over-year decrease.
* Q4 FY24 Results: Net profit for the quarter ended December 2024 was ₹8.09 crore, with sales rising 41.70% to ₹300.31 crore compared to the same period in the previous year.
* FY24 Annual Performance: For the full financial year ended 2024, Solara Active Pharma Sciences Ltd posted a loss of ₹-566.96 crore on a total income of ₹1,288.92 crore.
* Market Capitalization: ₹2,293 crore (as of recent trading sessions)
* 52-Week High Share Price: ₹885.95
* 52-Week Low Share Price: ₹441.10
* Promoter Holding: 37.94% (as of Mar 2025), increasing from 37.27% (as of Jun 2024)
* Q1 FY25 Net Sales: ₹273.01 crore
* Q1 FY25 Net Loss: ₹2.10 crore
* FY24 Annual Net Loss: ₹-566.96 crore
* FY24 Annual Total Income: ₹1,288.92 crore
Solara Active Pharma Sciences boasts robust manufacturing and R&D infrastructure:
* Manufacturing Plants: The company operates six manufacturing plants located in Ambernath, Mangalore, Mysore, Puducherry, Vishakhapatnam, and Cuddalore. These facilities have a combined capacity of over 2,000 kilolitres.
* R&D Centres: Two dedicated R&D Centres are situated in Chennai and Bengaluru, complementing the R&D efforts at its four API manufacturing facilities. Over 140 scientists are engaged in research and development.
* Regulatory Approvals: The company's manufacturing facilities have received stringent regulatory approvals from numerous international agencies, ensuring high-quality standards. These approvals include:
* United States Food and Drug Administration (USFDA)
* European Directorate for the Quality of Medicines (EDQM)
* Korea Food & Drug Administration (KFDA) - South Korea
* Euro Zone - Good Manufacturing Practice (EUGMP) - Danish
* World Health Organization (WHO) - Geneva
* Medicines and Healthcare products Regulatory Agency (MHRA)
* Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico
* Therapeutic Goods Administration (TGA) - Australia
* Pharmaceuticals and Medical Devices Agency (PMDA) - Japan
In a testament to its commitment to quality, Solara Active Pharma Sciences achieved a significant milestone:
* US FDA Inspection: The US FDA inspected a Solara facility from May 5th to 9th, 2025. The inspection concluded that the site is in an 'Acceptable State of Compliance' with zero Form 483 inspectional observations. This marks the third consecutive successful inspection outcome with zero 483 observations across Solara's network of manufacturing facilities.
Solara Active Pharma Sciences offers a diversified and high-value product portfolio:
* Commercial APIs: Its portfolio comprises over 60 commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues.
* Therapeutic Areas: The company offers APIs for a wide array of therapeutic areas, including but not limited to, amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti-hyperlipidemic, anti-arrhythmic agents, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotics, anticonvulsants, antidepressants, antifibrinolytics, antifungal, antigout agents, antihistamines, antimycotics, antineoplastic detoxifying agents, antiprotozoal agents, antipsoriatic, antipsychotic, antitubercular, antiulcer, anxiolytic, cardiovascular agents, and treatments for various chronic conditions like hyperphosphatemia and hypercholesterolemia.
* Global Reach: The business extends across North America, Europe, Japan, South Korea, the Middle East, and North Africa, offering a basket of niche and high-value products.
With a strong focus on innovation, Solara Active Pharma Sciences maintains robust R&D capabilities:
* Scientific Manpower: The company employs over 140 scientists across its two dedicated R&D Centres in Bengaluru and Chennai, and its four API manufacturing facilities.
* Product Pipeline: These state-of-the-art R&D facilities are working on a pipeline of over 25 products at various stages of development, ensuring future growth and market relevance.
The promoter holding in Solara Active Pharma Sciences Ltd has shown an upward trend, increasing to 37.94% as of March 2025 from 37.27% as of June 2024. The key promoters are DEVICAM CAPITAL LLP and PRONOMZ VENTURES LLP, who collectively own 21.1% of the total equity.
Solara Active Pharma Sciences is strategically positioned for future growth and market leadership:
* Demerger and Expansion: The company has approved the incorporation of a wholly-owned subsidiary in relation to the proposed demerger of its CRAMS (Contract Research and Manufacturing Services) and Polymers Business into an independent listed entity, aiming to unlock specialized value.
* Regulatory Focus: It continues to emphasize expanding its regulatory approvals and manufacturing capabilities to effectively serve global pharmaceutical markets.
* Credit Rating: CRISIL has reaffirmed Solara's ₹1,484 crore bank loan rating at 'BBB stable' and 'A3+ short term,' reflecting the company's sound financial position and operational strength in the competitive API manufacturing sector.
Solara Active Pharma Sciences' strategic focus remains on delivering high-quality APIs while maintaining stringent regulatory compliance across its global operations, positioning itself as a reliable and growing partner for pharmaceutical companies worldwide.
